Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(3 years from now) | |
US6794410
(Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(3 years from now) | |
US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(7 years from now) | |
US8802735
(Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(7 years from now) | |
US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(10 years from now) | |
US9186346
(Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Apr 30, 2024 |
Pediatric Exclusivity (PED) | Oct 30, 2024 |
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose
Dosage: TABLET;ORAL
17
United States
6
European Union
4
China
3
Peru
3
Israel
2
Portugal
2
Uruguay
2
Russia
2
Spain
2
Costa Rica
2
New Zealand
2
Argentina
2
Taiwan, Province of China
2
Hong Kong
2
Honduras
2
Canada
2
Cyprus
2
Slovenia
2
Ukraine
2
Chile
2
Australia
2
Denmark
1
United Kingdom
1
Germany
1
Malaysia
1
Panama
1
Guatemala
1
Jordan
1
Brazil
1
Croatia
1
Colombia
1
Dominican Republic
1
Austria
1
Mexico
1
Morocco
1
Korea, Republic of
1
Belgium
1
Tunisia
1
Nicaragua
1
Lithuania
1
Japan
1
Luxembourg
1
Hungary
1
ME
1
Poland
1
Ecuador
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic